Clinical Trials Browser

Phase 1/2 × temsirolimus × Clear all

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

Glioblastoma

NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Phase 1/2 Completed

9 enrolled 8 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01016769 2019-06-26

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Phase 1/2 Completed

48 enrolled 15 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00949325 2019-03-11

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Phase 1/2 Completed

24 enrolled 14 charts

Chondrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 1/2 Completed

92 enrolled 24 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02423954 2018-07-02

NivoPlus

Phase 1/2 Terminated

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00022724 2018-06-26

CCI-779 in Treating Patients With Malignant Glioma

Phase 1/2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Completed

48 enrolled 14 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01090466 2018-02-06

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Phase 1/2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01078142 2017-09-11

BERT

Phase 1/2 Completed

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT00921310 2016-12-13

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Phase 1/2 Terminated

12 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01335074 2016-11-15

Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT00112736 2015-06-15

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1/2 Completed

69 enrolled 12 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00483262 2013-11-11

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

63 enrolled 11 charts

Multiple Myeloma

NCT01015664 2012-12-17

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck